Boston, United States
Strand Therapeutics, founded in 2017, is at the cutting edge of Biotechnology and mRNA therapeutics, with headquarters in the United States. The company distinguishes itself with the slogan, "Where synthetic biology meets RNA therapeutics." Originating from MIT, Strand is pioneering the fusion of synthetic biology and therapeutic genetics by creating a proprietary mRNA programming language.
Strand aims to revolutionize mRNA therapies by enhancing their safety and efficacy through innovative programming of protein expression parameters within the human body. This is achieved via mRNA-encoded logic circuits that can initiate cell-type specific expressions and dynamically control protein dosage by interacting with small molecules.
The company's potential is underscored by securing a $45.00M Series A investment on 28 November 2022 from renowned investors, including Playground Global, FPV Ventures, Potentum Partners, and the Eli Lilly & Company Foundation. This funding will likely bolster Strand's position in life sciences and pharmaceutical innovation.
